HC Wainwright Reiterates Buy Rating for ImmunityBio (NASDAQ:IBRX)

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $8.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 178.75% from the company’s current price. HC Wainwright also issued estimates for ImmunityBio’s Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.45) EPS, FY2026 earnings at ($0.36) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at $0.03 EPS and FY2029 earnings at $0.29 EPS.

Several other research analysts have also commented on IBRX. D. Boral Capital reiterated a “buy” rating and set a $30.00 price objective on shares of ImmunityBio in a research note on Thursday. BTIG Research began coverage on shares of ImmunityBio in a research note on Friday, January 10th. They set a “buy” rating and a $6.00 price target on the stock. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $12.19.

ImmunityBio Stock Down 1.0 %

NASDAQ IBRX opened at $2.87 on Thursday. The firm has a market cap of $2.45 billion, a PE ratio of -3.12 and a beta of 0.82. The company has a 50 day moving average price of $3.08 and a 200 day moving average price of $3.66. ImmunityBio has a 52 week low of $2.28 and a 52 week high of $10.53.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.11. The firm had revenue of $7.55 million for the quarter, compared to the consensus estimate of $8.74 million. On average, equities research analysts anticipate that ImmunityBio will post -0.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. GSA Capital Partners LLP boosted its holdings in shares of ImmunityBio by 290.3% in the 3rd quarter. GSA Capital Partners LLP now owns 107,985 shares of the company’s stock valued at $402,000 after acquiring an additional 80,318 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of ImmunityBio in the 3rd quarter valued at $253,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of ImmunityBio by 2.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,265,981 shares of the company’s stock valued at $4,709,000 after acquiring an additional 29,665 shares during the last quarter. Advantage Alpha Capital Partners LP purchased a new stake in shares of ImmunityBio in the 3rd quarter valued at $257,000. Finally, Quantbot Technologies LP purchased a new stake in shares of ImmunityBio in the 3rd quarter valued at $143,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.